HK1133258A1 - Methods of synthesizing pharmaceutical salts of a factor xa inhibitor - Google Patents

Methods of synthesizing pharmaceutical salts of a factor xa inhibitor

Info

Publication number
HK1133258A1
HK1133258A1 HK10100268.3A HK10100268A HK1133258A1 HK 1133258 A1 HK1133258 A1 HK 1133258A1 HK 10100268 A HK10100268 A HK 10100268A HK 1133258 A1 HK1133258 A1 HK 1133258A1
Authority
HK
Hong Kong
Prior art keywords
inhibitor
factor
methods
pharmaceutical salts
synthesizing pharmaceutical
Prior art date
Application number
HK10100268.3A
Other languages
English (en)
Inventor
James P Kanter
Keiko Sujino
Sharique Sami Zuberi
Robert M Scarborough
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of HK1133258A1 publication Critical patent/HK1133258A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/90—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having more than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
HK10100268.3A 2006-11-02 2010-01-11 Methods of synthesizing pharmaceutical salts of a factor xa inhibitor HK1133258A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86414506P 2006-11-02 2006-11-02
PCT/US2007/083394 WO2008057972A1 (en) 2006-11-02 2007-11-01 Methods of synthesizing pharmaceutical salts of a factor xa inhibitor

Publications (1)

Publication Number Publication Date
HK1133258A1 true HK1133258A1 (en) 2010-03-19

Family

ID=39167635

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10100268.3A HK1133258A1 (en) 2006-11-02 2010-01-11 Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
HK12106397.2A HK1165426A1 (en) 2006-11-02 2012-06-29 Methods of synthesizing pharmaceutical salts of a factor xa inhibitor xa

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12106397.2A HK1165426A1 (en) 2006-11-02 2012-06-29 Methods of synthesizing pharmaceutical salts of a factor xa inhibitor xa

Country Status (10)

Country Link
US (2) US8524907B2 (xx)
EP (2) EP2077995B1 (xx)
CN (1) CN101595092B (xx)
AT (1) ATE544749T1 (xx)
AU (1) AU2007317376B2 (xx)
CA (1) CA2667488C (xx)
ES (2) ES2550057T3 (xx)
HK (2) HK1133258A1 (xx)
PT (2) PT2077995E (xx)
WO (1) WO2008057972A1 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
NZ567992A (en) 2005-11-08 2011-05-27 Millennium Pharm Inc Pharmaceutical salts and polymorphs of N-(5-chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide, a factor Xa inhibitor
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
EP2077995B1 (en) * 2006-11-02 2012-02-08 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
WO2008127682A2 (en) 2007-04-13 2008-10-23 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
CA2784921A1 (en) * 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor xa inhibitor
EP2513058B1 (en) * 2009-12-17 2016-11-09 Millennium Pharmaceuticals, Inc. Methods of synthesizing factor xa inhibitors
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
TW201221128A (en) 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CN104341343B (zh) * 2013-07-24 2018-09-28 四川海思科制药有限公司 贝曲西班的晶型及其制备方法和用途
CN104693114B (zh) * 2013-12-10 2019-08-16 四川海思科制药有限公司 一种贝曲西班的改进的制备方法
CN105085387A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 贝曲西班盐及其制备方法和用途
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
WO2017091757A1 (en) 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
CN105348187B (zh) * 2015-12-02 2017-12-08 安徽省逸欣铭医药科技有限公司 一种贝曲西班结构类似物及其制备方法和用途
CN105732490A (zh) * 2016-03-25 2016-07-06 重庆医科大学 一种贝曲西班的制备方法
EP3293174A1 (en) * 2016-09-09 2018-03-14 Sandoz Ag Crystalline salts of betrixaban
WO2018229796A2 (en) * 2017-06-14 2018-12-20 Mylan Laboratories Limited A process for betrixaban hydrochloride and betrixaban maleate salt
CN108570003A (zh) * 2018-06-01 2018-09-25 浙江宏元药业股份有限公司 一种贝曲西班马来酸盐的一水无定形及其制备方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2095619A (en) 1937-10-12 Aryl oxides
CH479557A (de) 1961-09-11 1969-10-15 Wander Ag Dr A Verfahren zur Herstellung neuer mehrbasischer Verbindungen
GB1047245A (xx) 1963-02-15
GB2095239B (en) 1981-02-27 1985-03-06 Torii & Co Ltd Novel amidine compounds
US4500714A (en) 1981-10-15 1985-02-19 Chugai Seiyaku Kabushiki Kaisha 3-Substituted-ureido-N-pyridyl benzamides
US4588587A (en) 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
JPS59181257A (ja) 1983-03-31 1984-10-15 Chugai Pharmaceut Co Ltd ウレイドベンズアミド誘導体
JP2668231B2 (ja) 1987-12-29 1997-10-27 大日精化工業株式会社 電子写真感光体
AU606808B2 (en) 1988-06-29 1991-02-14 Otsuka Pharmaceutical Factory, Inc. Arylcarboxamide substituted by alkylphosphonates, process for preparing the same and a pharmaceutical composition containing the same
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
JPH08504769A (ja) 1992-12-15 1996-05-21 コルバス・インターナショナル、インコーポレイテッド 因子Ｘａの新規インヒビター
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
US5610335A (en) 1993-05-26 1997-03-11 Cornell Research Foundation Microelectromechanical lateral accelerometer
TW300888B (xx) 1994-12-02 1997-03-21 Yamanouchi Pharma Co Ltd
EP0742208A1 (en) 1995-05-05 1996-11-13 Grelan Pharmaceutical Co., Ltd. 2-Ureido-benzamide derivatives
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
US5994375A (en) 1996-02-12 1999-11-30 Berlex Laboratories, Inc. Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants
JP2000516234A (ja) 1996-08-16 2000-12-05 デュポン ファーマシューティカルズ カンパニー アミジノフェニル―ピロリジン類、アミジノフェニル―ピロリン類、およびアミジノフェニル―イソオキサゾリジン類およびそれらの誘導体
JP2002511836A (ja) 1996-09-09 2002-04-16 スミスクライン・ビーチャム・コーポレイション 化合物および方法
ATE236890T1 (de) 1996-12-23 2003-04-15 Bristol Myers Squibb Pharma Co Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer
CZ225699A3 (cs) 1996-12-23 2000-09-13 Du Pont Pharmaceuticals Company Dusíkaté heteroaromatické sloučeniny jako inhibitory faktoru Xa
CA2293824A1 (en) 1997-06-19 1998-12-23 Mimi Lifen Quan (amidino)6-membered aromatics as factor xa inhibitors
IL133621A0 (en) 1997-06-26 2001-04-30 Lilly Co Eli Antithrombotic agents
AU8270698A (en) 1997-06-26 1999-01-19 Eli Lilly And Company Antithrombotic agents
CA2295153A1 (en) 1997-06-26 1999-01-07 Gerald Floyd Smith Antithrombotic agents
IL133623A0 (en) 1997-06-26 2001-04-30 Lilly Co Eli Antithrombotic agents
CA2295620A1 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. 5,6-heteroaryl-dipyrido¬2,3-b:3',2'-f|azepines and their use in the prevention or treatment of hiv infection
KR20010023364A (ko) 1997-08-27 2001-03-26 간자와 무츠와 3-아미디노아닐린 유도체, 활성화 혈액응고 제 ｘ 인자저해제 및 그것의 제조중간체
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
RU2226529C2 (ru) 1997-12-19 2004-04-10 Шеринг Акциенгезельшафт Производные ортоантраниламида в качестве антикоагулянтов, фармацевтическая композиция и способ лечения
EP0937711A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
JPH11302177A (ja) 1998-04-27 1999-11-02 Otsuka Pharmaceut Factory Inc 腎炎治療剤
EA200100639A1 (ru) 1998-12-09 2002-06-27 Американ Хоум Продактс Корпорейшн Производные тиомочевины, содержащие гетероциклический карбоксамид и защитную группу фенилэтиленамина, в качестве ингибиторов вирусов герпеса
JP2002531545A (ja) 1998-12-09 2002-09-24 ワイス ヘルペスウイルスのチオ尿素インヒビター
WO2000034237A2 (en) 1998-12-09 2000-06-15 American Home Products Corporation Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses
SK7682001A3 (en) 1998-12-09 2002-07-02 Wyeth Corp Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group
WO2000034269A1 (en) 1998-12-09 2000-06-15 American Home Products Corporation Thiourea inhibitors of herpes viruses
PT1137645E (pt) 1998-12-09 2004-09-30 Wyeth Corp Inibidores virus de herpes a base de tioureia alfa-metilbenzilada contendo um grupo fenilenodiamina
JP2002531557A (ja) 1998-12-09 2002-09-24 ワイス ヘルペスウイルスのチオ尿素インヒビター
EP1140903B1 (en) 1998-12-23 2004-08-04 Eli Lilly And Company Aromatic amides
KR20020047175A (ko) 1999-09-17 2002-06-21 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자의 억제제
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
ATE311366T1 (de) 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
RS53403A (xx) * 2000-12-29 2006-10-27 Pfizer Limited Postupak za dobijanje amlodipin maleata
US7312235B2 (en) 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
EP1678161B1 (en) 2003-10-09 2009-12-30 Millennium Pharmaceuticals, Inc. Thioether-substituted benzamides as inhibitors of factor xa
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
AU2005257999B2 (en) 2004-06-18 2011-12-08 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
NZ567992A (en) 2005-11-08 2011-05-27 Millennium Pharm Inc Pharmaceutical salts and polymorphs of N-(5-chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide, a factor Xa inhibitor
WO2007112367A2 (en) 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
EP2077995B1 (en) * 2006-11-02 2012-02-08 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
CN105193799A (zh) 2006-12-08 2015-12-30 米伦纽姆医药公司 使用经口因子xa抑制剂治疗血栓形成的单位剂量调配物和方法
EP2114930A2 (en) 2007-01-05 2009-11-11 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
WO2008127682A2 (en) 2007-04-13 2008-10-23 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
PT2146705E (pt) 2007-05-02 2014-05-23 Portola Pharm Inc Terapia de combinação com um composto que atua como inibidor do recetor de adp de plaquetas
EP2513058B1 (en) * 2009-12-17 2016-11-09 Millennium Pharmaceuticals, Inc. Methods of synthesizing factor xa inhibitors

Also Published As

Publication number Publication date
EP2077995A1 (en) 2009-07-15
AU2007317376A1 (en) 2008-05-15
HK1165426A1 (en) 2012-10-05
ES2382055T3 (es) 2012-06-04
ATE544749T1 (de) 2012-02-15
CN101595092B (zh) 2012-02-01
US20140046071A1 (en) 2014-02-13
CN101595092A (zh) 2009-12-02
US20100197929A1 (en) 2010-08-05
US8524907B2 (en) 2013-09-03
US9221758B2 (en) 2015-12-29
PT2077995E (pt) 2012-05-10
CA2667488A1 (en) 2008-05-15
EP2404906A1 (en) 2012-01-11
ES2550057T3 (es) 2015-11-04
PT2404906E (pt) 2015-11-02
AU2007317376B2 (en) 2013-01-17
WO2008057972A1 (en) 2008-05-15
EP2404906B1 (en) 2015-07-15
EP2077995B1 (en) 2012-02-08
CA2667488C (en) 2015-07-07

Similar Documents

Publication Publication Date Title
HK1165426A1 (en) Methods of synthesizing pharmaceutical salts of a factor xa inhibitor xa
TNSN08407A1 (en) Organic compounds
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
NZ592497A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
CY1111671T1 (el) Ετεροκυκλικη ενωση
WO2010014930A3 (en) Piperidine derivatives as jak3 inhibitors
ME01992B (me) Jedinjenje diarilhidantoina
NO20084783L (no) Syntese av acylaminoalkenylenamider nyttige som substans P antagonister
RS53292B (en) CRYSTAL FORMS 2-THIAZOLYL-4-HINOLINYL-OXY DERIVATIVES, POWERFUL HCV INHIBITOR
NZ592533A (en) METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR
HK1153739A1 (en) Spirocyclic derivatives as histone deacetylase inhibitors
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
EA200801381A1 (ru) Производные пиримидина
RS53503B1 (en) AMORPHIC AND CRYSTAL FORM GENZ 112638 HEMITARTARATE AS A GLYCOSILKERAMIDE SYNTHASIS INHIBITOR
DE602005019316D1 (en) Aromatische etherderivate als thrombin-hemmer
DE602005016297D1 (de) Antithrombotische diamide
MX2009012125A (es) Compuestos terapeuticos.
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
EA201170617A1 (ru) Пиразолиламинопиридины в качестве ингибиторов fak
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
WO2009154754A3 (en) Synthesis of deuterated morpholine derivatives
PT2049480E (pt) Derivados de 2-arilindole como inibidores da mpges-i
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
ECSP11011081A (es) 3-aminociclopentancarboxamidas

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211103